FLASH NOTE

WORLD EQUITIES: MID-YEAR SCENARIO UPDATE

WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?

Authors

JACQUES HENRY jhenry@pictet.com

JULIEN HOLTZ jholtz@pictet.com

SUMMARY

Developed-market (DM) equities

- > Equities have benefited from a positive feedback loop in 2021, with stronger economic recovery increasing sales growth, improving margins and earnings set to rebound by 40% in 2021 in the US and Europe.
- > The Q2 21 reporting season is set see a continuation of the recent trend of positive earnings surprises given the base effect comparison with last year will be particularly strong and bullish guidance from companies. Earnings growth in 2022 is expected to be healthy (over 10%).
- > Equity valuations are rich but expected to gradually ease as equity positioning is bullish but not extreme.
- > After cyclical stocks' strong outperformance versus defensives as the pandemic began to wind down, markets are becoming less polarised. As inflation fears abate, sovereign yields have fallen again, favouring growth relative to value.
- > Cash returns to shareholder are expected to be key again for equity returns going forward after equities' strong price performance in H1. The Fed has already removed payout constraints on US banks and the ECB is set to follow suit in 2H.
- > After the strong recovery and upgrade to our year-end targets (4375 for the S&P 500 and 465 for Stoxx Europe 600) to take into account stronger earnings than initially expected, we are keeping a neutral stance on equities overall.

Emerging-market (EM) equities

- > The strong momentum that lifted EM equities at the start of the year was abruptly interrupted by the rise in US real yields and a pullback in Chinese equities.
- > Latin America and EEMEA outperformed the broad MSCI EM index during H1 on the back of fast rising commodity prices and stronger post-covid catch-up potential.
- > We remain cautious on the outlook for EM equities in 2H2021 despite a supportive backdrop of strong economic growth in the context of a global reopening
- The inherent inertia to China's credit normalisation, the risk of a brisk rise in US real yields and the lag in vaccination campaigns in a number of EM countries remain tangible risks for EM equities.
- > We maintain our year-end target of USD1,400 for the MSCI EM (~5% upside), with a chance that the actual outcome is slightly higher.



WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?

DM equities: tailwind from earnings recovery

In the first half of 2021, the S&P 500 posted a stellar 15.3% return (in USD) and the Stoxx Europe 600 +15.2% (in euros), with the recovery in earnings the cornerstone of this performance. With our year-end price target having already been reached, it is time to reassess our outlook for the rest of 2021.

Earnings, earnings and more earnings

The economic recovery from the pandemic has been rapid and even stronger than expected in the scenario we set out at the start of this year. This has translated into 2021 sales growth now expected to be 12.7% by consensus for the S&P 500, up from an expectation of around 8% back in December. The trend has been similar for the Stoxx Europe 600, with current expectations close to 12% compared with less than 7% six months ago.

Along with sales, there has been a synchronised rebound in margins in Europe and the US. Both operating and net margins are expected to rise above pandemic levels on both sides of the Atlantic this year. The recovery in margins has been strongest the oil & gas and cyclicals, the sectors most battered by the pandemic in 2020. The recovery has been slightly different between European and US equity indexes, given the prevalence of high-flying tech names on the latter that have been recording all-time high margins, far above the level prevailing before the pandemic. In Europe, margins this year could move above where they were in 2011, before the euro sovereign debt crisis. But further improvements in margins could prove challenging as European equities lack technology sectors with high margins.




CHART 1: 12-MONTH FORWARD NET MARGIN US AND EUROPE

Strong top-lines and record margins are sending earnings growth through the roof in 2021. Consensus expectations are for earnings growth of 43% for the Stoxx Europe 600 and of almost 39% for the S&P 500. 2021 earnings level are now expected above their 2019



WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?

level in all major developed equity markets, ie the pandemic is looking behind us, a major achievement. In our new top-down scenario we expect that 2021 earnings growth could reach 45% in the US and 50% in Europe.



Further earnings upside


Consensus expectations for earnings growth in Q1 are exceptionally high—60% on the S&P 500 and over 100% for Stoxx Europe 600. Despite such high expectations, two factors could contribute to positive surprises: base effects and guidance. First, the collapse in earnings by around a third in the US and by half in Europe at the height of the pandemic in Q2 2020 mean the base effect is very strong. Second, bullish earnings guidance points to positive earnings surprises. Historically, an average of two-thirds of S&P 500 companies have issued negative guidance before earnings announcements. Since H2 2020, 2/3 of companies have issued positive guidance (see chart 5), fuelling strong positive earnings surprises since then. Pandemic-related uncertainties meant few companies were willing to provide guidance, but the numbers have picked up over the past four quarters. So far, 103 S&P 500 companies have provided guidance for Q2 2021, within the historical range of 100-120, meaning that Q2 21 guidance is significant. With the noticeable exceptions of energy and financials, where few pointers have been provided, positive guidance is well distributed across sectors, with materials, IT, communication services, industrials and healthcare providing the best.



WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?



CHART 5: SPLIT BETWEEN S&P 500 COMPANIES PROVIDING NEGATIVE AND POSITIVE GUIDANCE



Usually, the tendency is for analysts to start out with over-optimistic earnings expectations and then to revise them downwards as results come in. The opposite tends to hold true during economic recoveries, and the 2020 pandemic is no exception. Since summer 2020 in the US and January 2021 in Europe, both 2021 and 2022 earnings have been steadily upgraded by analysts. Yet earnings strength for 2021 have been pushing down 2022 earnings growth expectations – around 12% for the S&P 500 and Stoxx Europe 600. In 2022, apart from the US travel & leisure sector, the base effects boosting earnings growth this year will have vanished. Structural growers are expected to lead the pack n earnings again some time in 2022 as the cyclical recovery fades. Important risks to corporate earnings are an increase of corporate tax rate in the US and the implementation of a 15% global minimum tax rate in the OECD.

Positioning and valuation

With 12-month forward earnings ratios of 21.6x for the S&P 500 and 16.7x for the Stoxx Europe 600, equity valuations remain rich, having only marginally eased from 22.8x and 17.4x, respectively, at the end of last year. While the European discount tends to shrink dramatically when sector differences are taken into account, a sector-adjusted analysis shows that European stocks are still cheaper than their US peers. Cyclical sectors in the US and Europe still generally carry valuations far above the levels prevailing before the coronavirus outbreak. The US technology complex is still being paid at a 12-month forward price-earnings (PE) ratio of 24.5X, a premium to the overall market.



WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?

CHART 6: 12-MONTH FORWARD PE




Equities also look expensive relative to sovereign yields, despite the recent increase in the equity-risk premium (ERP), the difference between the 12-month forward price-earnings yield and 10-year government bonds. At 3.2% for the S&P 500, the ERP is around the level that prevailed for most of 2018 but is still below the 4.25% average of the past decade. This suggests there is potential for further compression in equity valuations in the second half of 2021 in line with our initial 2021 scenario with around 10% derating. Our year- end PE target stands at 20.1x in the US and 14.9x in Europe.

We do not forecast a massive equity valuation derating as earnings momentum remains supportive and equity positioning, while bullish, is not extreme. Inside systematic strategies, hedge funds exhibit a fairly high beta to equity, especially CTA strategies. At the same time, risk-parity strategies' exposure to equities has remained fairly low since March 2021. We estimate a basic risk-parity strategy focused on the S&P 500 and 10-year US Treasuries has an average exposure of 26% to the former, below the 35% long-term average. Volatility trends also suggest that investors are not overly optimistic. Since its March 2020 peak, volatility, as measured by the CBOE VIX index, has declined massively and now stands at 15x, at the lower bound of our standard volatility regime that ranges between 15x and 25x. While low, volatility is still above the level that prevailed in 2017, when the VIX index stood at around 10x for a few months. Skew, the volatility differential between options whose strike price is 10% above or below the spot price, remains quite high on the S&P 500 and above the early-March 2020 level. This suggests that while investors are bullish, they have put protection in place. For this reason, we are not overly pessimistic about equities and equity valuations.



WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?

CHART 7: S&P 500 AND EURO STOXX 50 SKEW




Rotation inside equities

The second part of 2020 and the beginning of 2021 witnessed a sharp sector rotation, with the incipient economic recovery pushing investors to favour cyclical sectors over defensive ones. Stripping out oil & gas, financials and TMT (technology, media and telecoms), our analysis shows that defensive sector massively outperformed cyclical ones before and at the height of the virus outbreak, but gave back more than their outperformance since then. Since mid-March 2021, defensives' underperformance has vanished, but defensive outperformance has been small and bound within a tight range, with investors still feeling that earnings figures may be too good to be true going forward.

The other popular way to look at equity rotation is to look at trends in 'value' and 'growth' stocks. Such analysis takes into account the sectors that we left aside in our previous cyclical / defensive analysis. Value / growth definition is not straightforward: there are as many definitions as index providers and index rebalancing can lead to massive shift of companies from one group to another (as happened in September 2020 and again in March 2021). Besides, the rate environment can impact the performance of growth versus value. Historically, the value versus growth trade tends to be more volatile and to perform better when interest rates are rising. Since mid-May 2021, growth has been outperforming value again as a result of a pause in the rise in sovereign yields.



WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?



Cash returns to become important

After the strong post covid-19 rally, the potential for further increases in equity indexes looks reduced. Indeed, the S&P 500 returned 38% from end-June 2020 to end-June 2021, compared with a long-term annual average of below 9%. Limited price performance may mean cash returns play a greater role in shareholder returns from now on.

Market strength and dividend cuts (mainly in Europe) mean that dividend yields have declined over the past few months. Currently, the 12-month forward dividend yield stands at 3% on the Stoxx Europe 600 and slightly below 1.5% on the S&P 500. Overall, US companies preserved dividends during the pandemic, whereas lower earnings and regulatory constraints pushed European companies to slash dividend payouts. The Fed's decision to lift restrictions on US banks paying out dividends and buying back their shares should provide an additional boost to the sector. In Europe, dividend expectations are still below their pre-pandemic levels, Things should improve after the result of stress tests on euro area banks are known at the end of July. A return to the pay-out ratio to the pre-pandemic level of around 50% (from the current maximum of around 15%) could translate into Stoxx Europe 600 banks paying out EUR37 bn in dividends in 2022.


Buybacks are the other way for companies to reward shareholders. Historically, they have been more important in the US than in Europe. With the exception of tech-related names (IT and communication services), buybacks collapsed in the US in 2020. The strong rebound in Q1 2021 (from USD105 bn in Q4 20 to USD191 bn in Q1 21) was largely driven by the financial sector. We expect buyback figures to improve further as US banks restart buying back shares in H2 21, keeping in mind that US banks paid out as much as IT in



WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?

2019. Financials, and especially banks, are also key to European dividends and buybacks and are expected to become more substantial in the coming months.

CHART 10: S&P 500 BUYBACKS (IN USD BN)



Revising up our 2021 year-end target

Owing to mild valuation compression and stronger earnings than we expected at the start of this year, we are revising up our year-end price target for 2021 for all major equity indices. Our new target is 4,375 for the S&P 500 and 465 for the Stoxx Europe 600. This compares to levels of 4358 for the S&P 500 and 460 for the Stoxx Europe on 6 July, indicating that we expect both indexes to make only modest extra gains over the remainder of 2021. Our neutral stance on equities balances the prospect of strong earnings with risks regarding corporate tax, bullish (but not extreme) equity positioning and rich equity valuations.



FLASH NOTE

WORLD EQUITIES: MID-YEAR SCENARIO UPDATE

WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?


EM equities: muddling through H2

A whirlwind start to the year

Coinciding with the US elections and very promising clinical results for mRNA-based covid-19 vaccines, EM equities had the wind at their back at the end of last year, but experienced difficulties again in February due to a combination of internal and external factors. The two main ones were the rise in US real rates and macroeconomic developments in China.

While long-term rates in the US had been rising since August 2020, the rise was driven by inflation expectations, whereas real rates remained stable. This changed in February 2021when the 10-year TIPS yield rose 50bps in the space of a couple of weeks (incidentally supporting a swift appreciation of the US dollar). Both the rise in global financing costs and in the US dollar put pressure on EM equities in general.

CHART 11: MSCI EM - TOTAL RETURN RELATIVE TO MSCI WORLD INDEX (REBASED ON 01.01.2021)



Source: PWM - AA&MR, Factset 7 July 2021

But the lag in EM equities' performance since February has also been largely driven by China, where equities' underperformance year-to-date has been due to two main factors.

First, there has been an exceptional drive to tighten the regulatory landscape in China in recent months. This has affected many sectors from consumer finance (e.g. Ant Financial) to internet platforms (e.g. Alibaba, Meituan) and after-school tutoring (e.g. TAL Education, New Oriental Education). While many thought regulatory zeal might weaken, we felt that more action could come after the Communist Party's centenary celebrations at the start of July. Indeed, last weekend regulators moved on several tech platforms, including the freshly listed Didi Chuxing ride-hailing app.

Second, Total Social Financing (TSF), a key indicator representing the aggregate amount of financing provided to the domestic Chinese economy, started decelerating in February. Fading stimulus is a significant headwind for Chinese earnings (as well as for EM



WHERE NEXT FOR EQUITIES AFTER A SPARKLING FIRST HALF?

earnings in general given the central role of the Chinese economy). The fact that China's was the first large economy to emerge from the pandemic—and therefore the first to see recovery momentum flag—may also affect earnings growth prospects.

While the picture has been looking unattractive at an aggregate level, EM equities exhibited significant internal rotation, with Latin America and Eastern Europe, Middle East and African (EEMEA) outperforming, notably thanks to red hot commodity prices. ASEAN countries, on the other hand, have been struggling to reopen their economies due to repeated covid-19 outbreaks and lagging vaccination campaigns. Year-to-date EEMEA is up +19%, Latin America +5% and EM Asia +4% (with the ASEAN subsegment down by -6%).

Clearer skies in H2? Not so fast

While the global macroeconomic backdrop of strong real GDP growth and relatively elevated inflation (we expect 6% and 3.8% respectively at the global level in 2021) coupled with accommodative fiscal and monetary policies are undoubtedly supportive of EM equities, it remains unclear at this stage whether the latter can outperform in 2H.

On the plus side, EM countries' growth advantage is set to widen in the second half of 2021, reaching a peak in 3Q21. A widening growth differential is known to drive the performance of EM equities relative to their DM peers--albeit with a significant lag. A more direct positive impact on EM equities could come from the 4% decline in the USD against other major currencies that we expect by the end of the year.

Nonetheless, there are still clouds on the horizon. First, a renewed rise in real US yields is a significant risk. We expect US 10-year TIPS yields to rise to -0.1% by the end of the year from -0.94% at the time of writing. This would be an even bigger move than the one we saw in February. While emerging markets are much less vulnerable than they were in 2013 during the so-called 'taper tantrum', EM equities would likely struggle in such a scenario.

Second, credit tightening cycles in China typically take about a year, based on past episodes in 2010, 2013 and 2018. This means a significant engine of earnings growth for EM equities could be missing at least until the end of the year. Meanwhile, the momentum observed on EM ex-China earnings could also fade should commodity prices – which tend to correlate with Chinese demand – stabilise.

Finally, covid-19 vaccination campaigns in EM (particularly in South East Asia and South Africa) have been lagging those in developed markets. The risk we see more lockdown measures to deal with further outbreaks (as is currently the case in Malaysia or Indonesia) remains a major risk as new variants of the coronavirus emerge.

We are maintaining our year-end target of USD 1,400 for the MSCI EM (compared with 1'347 on 6 July). Our upside scenario envisages the MSCI EM reaching USD1,500 should we see a stronger-than-expected depreciation of the US dollar, an unexpected acceleration of growth in China, or the emergence of a commodities 'supercycle'.



DISCLAIMERS

Distributors: Banque Pictet & Cie SA, Route des Acacias 60, 1211 Geneva 73, Switzerland, Pictet & Cie (Europe) S.A., 15A, avenue J. F. Kennedy, L-1855 Luxembourg/B.P. 687, L-2016 Luxembourg.

Banque Pictet & Cie SA is established in Switzerland, exclusively licensed under Swiss Law and therefore subject to the supervision of the Swiss Financial Market Supervisory Authority (FINMA).

Pictet & Cie (Europe) SA is established in Luxembourg, authorized and regulated by the Luxembourg Financial Authority, Commission de Surveillance du Secteur Financier.

This marketing communication is not intended for persons who are citizens of, domiciled or resident in, or entities registered in a country or a jurisdiction in which its distribution, publication, provision or use would violate current laws and regulations.

The information, data and analysis furnished in this document are disclosed for information purposes only. They do not amount to any type of recommendation, either general or tailored to the personal circumstances of any person. Unless specifically stated otherwise, all price information is indicative only. No entity of the Pictet Group may be held liable for such information, nor does it constitute an offer or an invitation to buy, sell or subscribe to securities or other financial instruments. The information contained herein is not the result of either financial analysis within the meaning of the Swiss Bankers Association's Directives on the Independence of Financial Research or of investment research for the purposes of the relevant EU MiFID provisions. All information and opinions expressed in this document were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy or completeness.

Except for any obligations that any entity of the Pictet Group might have towards the addressee, the addressee should consider the suitability of the transaction to individual objectives and independently assess with a professional advisor the specific financial risks as well as legal, regulatory, credit, tax and accounting consequences.

Furthermore, the information, opinions and estimates in this document reflect an evaluation at the date of initial publication and may be changed without notice. The Pictet Group is not under any obligation to update or keep current the information contained herein. If this document refers to the value and income of one or more securities or financial instruments, it is based on rates from the customary sources of financial information, which may fluctuate. The market value of financial instruments may vary on the basis of economic, financial or political changes, currency fluctuations, the remaining term, market conditions, the volatility and solvency of the issuer or the benchmark issuer. Some investments may not be readily realisable since the market in the securities can be illiquid. Moreover, exchange rates may have a positive or negative effect on the value, the price or the income of the securities or the related investments mentioned in this document. When investing in emerging countries, please note that the political and economic situation in such countries is significantly less stable than in industrialised countries, and they are much more exposed to the risks of rapid political change and economic setbacks.

Past performance must not be considered an indicator or guarantee of future performance, and the addressees of this document are fully responsible for any investments they make. No express or implied warranty is given as to future performance. Moreover, forecasts are not a reliable indicator of future performance. The content of this document may be read and/or used solely by its addressee. The Pictet Group is not liable for the use, transmission or exploitation of the content of this document. Therefore, any form of reproduction, copying, disclosure, modification and/or publication of the content is under the sole liability of the addressee of this document, and no liability whatsoever will be incurred by the Pictet Group. The addressee of this document agrees to comply with the applicable laws and regulations in the jurisdictions where they use the information reproduced in this document.

This document is issued by Banque Pictet & Cie SA. This publication and its content may be cited, provided that the source is indicated. All rights reserved. Copyright 2021.

Distributor: Pictet & Cie (Europe) S.A., London branch ("Pictet London Branch") This is a marketing communication distributed by Pictet London Branch.

This document sets forth neither a personal recommendation tailored to the needs, objectives and financial situation of any individual or company (investment advice as defined in the Financial Conduct Authority's Handbook of rules and guidance (the "FCA Handbook")), nor the results of investment research within the meaning of the FCA Handbook. Moreover, it does not constitute an offer, or an invitation to buy, sell or subscribe to securities or other financial instruments, nor is it meant as a proposal for the conclusion of any type of agreement. Furthermore, this document should not be considered a suitability report as Pictet London Branch has not received all the necessary information on the recipient to complete its suitability assessment, which covers the recipient's knowledge and experience, tolerance to risk, investment needs and the recipient's ability to absorb financial risk. Should its addressee decide to enter into any transaction in relation to a financial product referred to herein, this will be under the addressee's sole responsibility, and the suitability/appropriateness of the transaction and other financial, legal and tax aspects should be assessed by an expert.

Any information contained in this document is disclosed for information purposes only, and neither the producer nor the distributor can be held liable for any fluctuation in the price of the securities. No express or implied warranty is given as to future performance. The opinions expressed reflect an objective evaluation of information available to the general public, such as rates from customary sources of financial information. The market value of securities mentioned may vary on the basis of economic, financial or political changes, the remaining term, market conditions, the volatility and solvency of the issuer or the benchmark issuer. Moreover, exchange rates may have a positive or negative effect on the value, the price or the income of the securities or the related investments mentioned in this document. It is also expressly noted that forecasts are not a reliable indicator of future performance, while past performance is not a reliable indicator of future results.

You should take investment decisions only when you fully understand the relevant financial product and the risks involved. In particular, you must read the relevant product documentation (such as the issuance programme, final terms, prospectus, simplified prospectus and key (investor) information document), as well as Appendix 4: Risk Warnings Relating to Trading in Financial Instruments of the Terms and Conditions of Pictet London Branch. Structured products are complex financial products and involve a high degree of risk. The value of structured products depends not only on the performance of the underlying asset(s), but also on the credit rating of the issuer. Furthermore, the investor is exposed to the risk of default of the issuer/guarantor.

In respect of any product documentation, including key information documents of Packaged Retail and Insurance-based Investment Products ("KIDs") and key investor information documents of Undertakings for Collective Investment in Transferable Securities ("KIIDs"), please note that these may change without notice. You should therefore ensure that you review the latest version of them prior to confirming to Pictet London your decision to invest. If you have been provided with a link to access the respective



FLASH NOTE

PICTET WEALTH MANAGEMENT ASSET ALLOCATION & MACRO RESEARCH 08 July 2021

KID/KIID/other product document, you should click on the link immediately before confirming to Pictet London Branch your decision to invest so that you can review the most recent version of the respective KID/KIID/other product document. If you have not been provided with a link to access the relevant document, or if you are in any doubt as to what the latest version of the respective KID/KIID/other product document is, or where it can be found, please ask your usual Pictet London Branch contact.

Pictet London Branch is not the manufacturer of the product(s), and the KID/KIID/other product document is provided by a third party. The KID/KIID/other product document is obtained from sources believed to be reliable. Pictet London Branch does not make any guarantee or warranty as to the correctness and accuracy of the data contained in the KID/KIID/other product document. Pictet London Branch may not be held liable for an investment decision or other transaction made based on reliance on, or use of, the data contained in the KID/KIID/other product document.

By subscribing to the product(s) proposed herein, you acknowledge that you have (i) received, in good time, read and understood any relevant documentation linked to the product(s), including, where applicable, the respective KID/KIID/other product document; (ii) taken note of the product(s) restrictions; and (iii) met the applicable subjective and objective eligibility conditions to invest in the product(s).

Pictet London Branch may, if necessary, rely on these acknowledgements and receive your orders to transmit them to another professional or to execute them, according to the relevant clauses of your mandate, as well as the Terms and Conditions of Pictet London Branch.

The content of this document may be read and/or used solely by its addressee. Any form of reproduction, copying, disclosure, modification and/or publication in any form or by any means whatsoever is not permitted without the prior written consent of Pictet London Branch, and no liability whatsoever will be incurred by Pictet London Branch. The addressee of this document agrees to comply with the applicable laws and regulations in the jurisdictions where they use the information provided in this document.

Pictet London Branch is a branch of Pictet & Cie (Europe) S.A.. Pictet & Cie (Europe) S.A. is a société anonyme (public limited liability company) incorporated in Luxembourg and registered with the Luxembourg Registre de Commerce et des Sociétés (RCS no. B32060). Its head office is at 15A, avenue J.F. Kennedy, L-2016 Luxembourg. Pictet London Branch is registered as a UK establishment with Companies House (establishment number BR016925) and its UK establishment office address is Stratton House 6th Floor, London, 5 Stratton Street, W1J 8LA.

Authorised and regulated by the Commission de Surveillance du Secteur Financier. Deemed authorised by the Prudential Regulation Authority. Subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details of the Temporary Permissions Regime, which allows EEA-based firms to operate in the UK for a limited period while seeking full authorisation, are available on the Financial Conduct Authority's website.

Distributors: Bank Pictet & Cie (Asia) Ltd ("BPCAL") in Singapore, 10 Marina Blvd #22-01 Tower 2, Marina Bay, Financial Centre, Singapore 018983 and Pictet & Cie (Europe) S.A., Hong Kong branch ("Pictet HK branch") in Hong Kong. The registered address of Pictet HK branch is 9/F, Chater House, 8 Connaught Road Central, Hong Kong.

The information, tools and material presented in this document are provided for information purposes only and are not to be used or considered as an offer, an invitation to offer or solicitation to buy, sell or subscribe for any securities, commodities, derivatives, (in respect of Singapore only) futures, or other financial instruments (collectively referred to as "Investments") or to enter into any legal relations, or as advice or recommendation with respect to any Investments. This document is intended for general circulation and is not directed at any particular person. This document does not have regard to the specific investment objectives, financial situation and/or the particular needs of any recipient of this document. Investors should seek independent financial advice regarding the appropriateness of investing in any Investments or adopting any strategies discussed in this document, taking into account the specific investment objectives, financial situation or particular needs of the investor, before making a commitment to invest.

BPCAL/Pictet HK branch has not taken any steps to ensure that the Investments referred to in this document are suitable for any particular investor, and accepts no fiduciary duties to any investor in this regard. Furthermore, BPCAL/Pictet HK branch makes no representations and gives no advice concerning the appropriate accounting treatment or possible tax consequences of any Investment. Any investor interested in buying or making any Investment should conduct its own investigation and analysis of the Investment and consult its own professional adviser(s) about any Investment, including the risks involved with transactions on such Investment.

This document is not to be relied upon in substitution for the exercise of independent judgment. The value and income of any Investment mentioned in this document may fall as well as rise. The market value may be affected by, among other things, changes in economic, financial, political factors, time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Furthermore, foreign currency rates of exchange may have a positive or adverse effect on the value, price or income of any Investment mentioned in this document. Accordingly, investors must be willing and able to, and effectively assume all risks and may receive back less than originally invested.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, expressed or implied, is made by BPCAL/Pictet HK branch regarding future performance.

This document does not constitute the investment policy of BPCAL/Pictet HK branch, or an investment recommendation, and merely contains the different assumptions, views and analytical methods of the analysts who prepared them. Furthermore, the information, opinions and estimates expressed herein reflect a judgment at its original date of publication and are subject to change without notice and without any obligation on BPCAL/Pictet HK branch to update any of them. BPCAL/Pictet HK branch may have issued or distributed other reports or documents that are inconsistent with, and reach different conclusions from, the information presented in this document.

While the information and opinions presented herein are believed to be from sources considered to be reliable, BPCAL/Pictet HK branch is not able to and does not make any representation or warranty as to their accuracy or completeness. Accordingly, BPCAL/Pictet HK branch accepts no liability for any loss arising from the use of or reliance on this document, which is presented for information purposes only. BPCAL/Pictet HK branch reserves the right to act upon or use any of the information in this document at any time, including before its publication herein.

BPCAL/Pictet HK branch and its affiliates (or employees thereof) may or may not have long or short positions in, and buy or sell, or otherwise have interest in, any of the Investments mentioned herein, and may or may not have relationships with the issuers of or entities connected with Investments mentioned in this document. BPCAL/Pictet HK branch and their affiliates (or employees thereof) may act inconsistently with the information and/or opinions presented in this document.

The information used to prepare this document and/or any part of such information, may have been provided or circulated to employees and/or one or more clients of BPCAL/Pictet HK branch before this document was received by you and such information may have been acted upon by such recipients or by BPCAL/Pictet HK branch.

This document is provided solely for the information of the intended recipient and should not be reproduced, published, circulated or disclosed in whole or in part to any other person without the prior written consent of BPCAL/Pictet HK branch.



Singapore

This document is not directed to, or intended for distribution, publication to or use by, persons who are not accredited investors, expert investors or institutional investors as defined in section 4A of the Securities and Futures Act (Cap. 289 of Singapore) ("SFA") or any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject BPCAL and any of its affiliates or related corporations to any prospectus or registration requirements.

BPCAL has obtained an exemption from the Monetary Authority of Singapore ("MAS") under section 100(2) of the Financial Advisers Act ("FAA") for the provision of financial advisory services to High Net Worth Individuals (as defined in the MAS Guidelines on Exemption for Specialised Units Serving High Net Worth Individuals FAA-G07) (the "Exemption") and is exempted from the requirements of sections 25, 27, 28 and 36 of the FAA, the MAS Notice on Recommendations on Investment Products (FAA-N16), MAS Notice on Appointment and Use of Introducers by Financial Advisers (FAA-N02), MAS Notice on Information to Clients and Product Information Disclosure (FAA-N03) and MAS Notice on Minimum Entry and Examination Requirements for Representatives of Licensed Financial Advisers and Exempt Financial Advisers (FAA-N13).

Please contact BPCAL in Singapore in respect of any matters arising from or in connection with this document.

Hong Kong

This document is not directed to, or intended for distribution, publication to or use by, persons who are not "professional investors" within the meaning of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made thereunder (the "SFO") or any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject Pictet HK branch and any of its affiliates or related corporations to any prospectus or registration requirements.

Pictet & Cie (Europe) S.A. is incorporated in Luxembourg with limited liability. It is an authorised institution within the meaning of the Banking Ordinance and a registered institution (CE No.: AQ515) under the SFO carrying on Type 1 (dealing in securities), Type 4 (advising on securities) and Type 9 (asset management) regulated activities.

Warning: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. Please contact Pictet HK branch in Hong Kong in respect of any matters arising from, or in connection with this document.

Distributor: Pictet Bank & Trust Limited, whose registered office is located at Building 1, Bayside Executive Park, West Bay Street & Blake Road, Nassau, New Providence, The Bahamas.

The document is not directed to, or intended for distribution or publication to or use by persons who are not Accredited Investors (as defined in the Securities Industry Regulations, 2012) and subject to the conditions set forth in the Securities Industry Regulations, 2012 or to any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject Pictet Bank & Trust Limited to any prospectus or registration requirements. Pictet Bank & Trust Limited is incorporated in The Bahamas with limited liability. It is a bank and trust company that is licensed in accordance with the Banks and Trust Companies' Regulation Act and is regulated by the Central Bank of The Bahamas. Additionally, Pictet Bank & Trust Limited is registered with the Securities Commission of The Bahamas as a Broker Dealer II and is approved to (i) Deal in Securities 1.(a) & (c); (ii) Arrange Deals in securities; (iii) Manage Securities; (iv) Advise on Securities.

Warning: The content of this document has not been reviewed by any regulatory authority in The Bahamas. You are therefore advised to exercise caution when processing the information contained herein. If you are in any doubt about any of the content of this document, you should obtain independent professional advice.

